Shared evidence, different recommendations: a comparative analysis of Qdenga (TAK-003) dengue vaccine guidance for travellers across countries
Sarah L McGuinness, Dipti Patel, Helena H Askling, Camilla Rothe, Steven Schofield, Robert Steffen, Leo G Visser, Lin H Chen · 2026
Read Shared evidence, different recommendations: a comparative analysis of Qdenga (TAK-003) dengue vaccine guidance for travellers across countries by Sarah L McGuinness, Dipti Patel, Helena H Askling, Camilla Rothe, Steven Schofield, Robert Steffen, Leo G Visser, Lin H Chen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13621450.txt.
Description
Sarah McGuinness and co-authors compare national guidance on the dengue vaccine Qdenga for travellers, and find wide gaps from shared evidence. Qdenga is the first dengue vaccine written into traveller guidance in many countries. Survey answers came from eighteen advisory bodies in seventeen countries in 2026, joined with a structured read of public guidance.
All bodies agreed on vaccination for travellers with lab-confirmed past dengue. For those without past infection, advice ranged from no vaccine to vaccine based on trip risk alone. Bodies also differed on how they used trip length, repeat exposure and traveller traits, and on how past infection should be proven. Guidance was mostly stricter than the licence allows.
Catalog record
| CREATOR | Sarah L McGuinness, Dipti Patel, Helena H Askling, Camilla Rothe, Steven Schofield, Robert Steffen, Leo G Visser, Lin H Chen |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 52 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |